Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.
Terrence J. Bradley, MD
Advertisement
Articles by Terrence J. Bradley, MD
Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.
Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.
Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami in Health System, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).
Advertisement
Latest Updated Articles
Dr. Bradley on Ruxolitinib in Myeloproliferative NeoplasmsPublished: March 30th 2019 | Updated:
Dr. Bradley on Evolving Therapeutic Strategies in MPNsPublished: April 17th 2020 | Updated:
Dr. Bradley on the Challenges Faced in MPNsPublished: April 25th 2020 | Updated:
- Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia Vera
Published: April 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5